Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer

Current Medicinal Chemistry

Volumn 23, Issue 24, 2016, Pages 2618-2636

  Fionda, Cinzia ^a   Abruzzese, Maria Pia ^a   Santoni, Angela ^a,b   Cippitelli, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Cancer; Chemoimmunotherapy; Immune Escape; MDSCs; Microenvironment; Nitric Oxide; Nitric Oxide Donors; RNS; TAM

Indexed keywords

2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; ACETYLSALICYLIC ACID; AMINOGUANIDINE; CYCLOPHOSPHAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; IBUPROFEN; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; N6 (1 IMINOETHYL)LYSINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE NITROGEN SPECIES; IMMUNOSUPPRESSIVE AGENT; ISOPROTEIN; NITRIC OXIDE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL INTERACTION; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLEIOTROPY; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; IMMUNOTHERAPY; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASMS; PATHOLOGY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ISOFORMS; REACTIVE NITROGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84989187512     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160729104647     Document Type: Review

References (192)

1. Bredt D. S.; Hwang P. M.; Glatt C. E.; Lowenstein C.; Reed R. R.; Snyder S. H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature, 1991, 351(6329), 714-718.
2. Lowenstein C. J.; Glatt C. S.; Bredt D. S.; Snyder S. H. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl. Acad. Sci. USA, 1992, 89(15), 6711-6715.
3. Robinson L. J.; Weremowicz S.; Morton C. C.; Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics 1994, 19(2), 350-357.
4. Mocellin S.; Bronte V.; Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med. Res. Rev., 2007, 27(3), 317-352.
5. Muntane J.; la Mata M. D. Nitric oxide and cancer. World J. Hepatol., 2010, 2(9), 337-344.
6. Fukumura D.; Kashiwagi S.; Jain R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer, 2006, 6(7), 521-534.
7. Xu W.; Liu L. Z.; Loizidou M.; Ahmed M.; Charles I. G. The role of nitric oxide in cancer. Cell Res., 2002, 12(5-6), 311-320.
8. Shi Q.; Xiong Q.; Wang B.; Le X.; Khan N. A.; Xie K. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res., 2000, 60(10), 2579-2583.
9. Xu L.; Xie K.; Fidler I. J. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum. Gene Ther., 1998, 9(18), 2699-2708.
10. Bruns C. J.; Shinohara H.; Harbison M. T.; Davis D. W.; Nelkin G.; Killion J. J.; McConkey D. J.; Dong Z.; Fidler I. J. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res., 2000, 60(1), 2-7.
11. Di C. E.; Comes A.; Basso S.; De A.A.; Meazza R.; Musiani P.; Moelling K.; Albini A.; Ferrini S. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J. Immunol., 2000, 165(6), 3111-3118.
12. Jyothi M. D.; Khar A. Interleukin-2-induced nitric oxide synthase and nuclear factor-kappaB activity in activated natural killer cells and the production of interferongamma. Scand. J. Immunol., 2000, 52(2), 148-155.
13. Cifone M. G.; Ulisse S.; Santoni A. Natural killer cells and nitric oxide. Int. Immunopharmacol., 2001, 1(8), 1513-1524.
14. Perrotta C.; Falcone S.; Capobianco A.; Camporeale A.; Sciorati C.; De P. C.; Pisconti A.; Rovere-Querini P.; Bellone M.; Manfredi A. A.; Clementi E. Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. Cancer Res., 2004, 64(11), 3767-3771.
15. Wang H. H.; McIntosh A. R.; Hasinoff B. B.; Rector E. S.; Ahmed N.; Nance D. M.; Orr F. W. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: A natural hepatic defense against metastasis. Cancer Res., 2000, 60(20), 5862-5869.
16. Qiu H.; Orr F. W.; Jensen D.; Wang H. H.; McIntosh A. R.; Hasinoff B. B.; Nance D. M.; Pylypas S.; Qi K.; Song C.; Muschel R. J.; Al-Mehdi A. B. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am. J. Pathol., 2003, 162(2), 403-412.
17. De S.F.; Sandri S.; Ferrarini G.; Pagliarello I.; Sartoris S.; Ugel S.; Marigo I.; Molon B.; Bronte V. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. Front. Immunol., 2014, 5, 69.
18. Forstermann U.; Schmidt H. H.; Pollock J. S.; Sheng H.; Mitchell J. A.; Warner T. D.; Nakane M.; Murad F. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem. Pharmacol., 1991, 42(10), 1849-1857.
19. Alderton W. K.; Cooper C. E.; Knowles R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J., 2001, 357(Pt 3), 593-615.
20. Forstermann U.; Sessa W. C. Nitric oxide synthases: regulation and function. Eur. Heart J., 2012, 33(7), 829-837d.
21. Friebe A.; Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res., 2003, 93(2), 96-105.
22. Oliveira C. J.; Schindler F.; Ventura A. M.; Morais M. S.; Arai R. J.; Debbas V.; Stern A.; Monteiro H. P. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic. Biol. Med., 2003, 35(4), 381-396.
23. Jones M. K.; Tsugawa K.; Tarnawski A. S.; Baatar D. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem. Biophys. Res. Commun., 2004, 318(2), 520-528.
24. Zaragoza C.; Soria E.; Lopez E.; Browning D.; Balbin M.; Lopez-Otin C.; Lamas S. Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP-dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. Mol. Pharmacol., 2002, 62(4), 927-935.
25. Kawasaki K.; Smith R. S., Jr.; Hsieh C. M.; Sun J.; Chao J.; Liao J. K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell Biol., 2003, 23(16), 5726-5737.
26. Stamler J. S.; Singel D. J.; Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science, 1992, 258(5090), 1898-1902.
27. Wiseman H.; Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J., 1996, 313 ( Pt 1), 17-29.
28. Stamler J. S.; Lamas S.; Fang F. C. Nitrosylation. The prototypic redox-based signaling mechanism. Cell, 2001, 106(6), 675-683.
29. Heijnen H. F.; van D. E.; Slot J. W.; Fries D. M.; Blachard-Fillion B.; Hodara R.; Lightfoot R.; Polydoro M.; Spielberg D.; Thomson L.; Regan E. A.; Crapo J.; Ischiropoulos H. Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radic. Biol. Med., 2006, 40(11), 1903-1913.
30. Lipton S. A.; Choi Y. B.; Pan Z. H.; Lei S. Z.; Chen H. S.; Sucher N. J.; Loscalzo J.; Singel D. J.; Stamler J. S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds. Nature, 1993, 364(6438), 626-632.
31. Stamler J. S. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell, 1994, 78(6), 931-936.
32. Wink D. A.; Vodovotz Y.; Cook J. A.; Krishna M. C.; Kim S.; Coffin D.; DeGraff W.; DeLuca A. M.; Liebmann J.; Mitchell J. B. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc.), 1998, 63(7), 802-809.
33. Lala P. K.; Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol., 2001, 2(3), 149-156.
34. Laval F.; Wink D. A.; Laval J. A discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Rev. Physiol. Biochem. Pharmacol., 1997, 131(175-191.
35. Hsieh Y. S.; Wang H. C.; Tseng T. H.; Chang W. C.; Wang C. J. Gaseous nitric oxide-induced 8-nitroguanine formation in human lung fibroblast cells and cell-free DNA. Toxicol. Appl. Pharmacol., 2001, 172(3), 210-216.
36. Ohshima H. Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. Toxicol. Lett., 2003, 140-141, 99-104.
37. Ohshima H.; Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res., 1994, 305(2), 253-264.
38. Broillet M. C. S-nitrosylation of proteins. Cell Mol. Life Sci., 1999, 55(8-9), 1036-1042.
39. Hess D. T.; Matsumoto A.; Kim S. O.; Marshall H. E.; Stamler J. S. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol., 2005, 6(2), 150-166.
40. Matthews J. R.; Botting C. H.; Panico M.; Morris H. R.; Hay R. T. Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res., 1996, 24(12), 2236-2242.
41. Marshall H. E.; Hess D. T.; Stamler J. S. S-nitrosylation: physiological regulation of NF-kappaB. Proc. Natl. Acad. Sci. USA, 2004, 101(24), 8841-8842.
42. Marshall H. E.; Stamler J. S. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry, 2001, 40(6), 1688-1693.
43. Calmels S.; Hainaut P.; Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res., 1997, 57(16), 3365-3369.
44. Nikitovic D.; Holmgren A.; Spyrou G. Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. Biochem. Biophys. Res. Commun. 1998, 242(1), 109-112.
45. Tabuchi A.; Sano K.; Oh E.; Tsuchiya T.; Tsuda M. Modulation of AP-1 activity by nitric oxide (NO) in vitro: NO-mediated modulation of AP-1. FEBS Lett., 1994, 351(1), 123-127.
46. Liu H.; Colavitti R.; Rovira I. I.; Finkel T. Redoxdependent transcriptional regulation. Circ. Res., 2005, 97(10), 967-974.
47. Li F.; Sonveaux P.; Rabbani Z. N.; Liu S.; Yan B.; Huang Q.; Vujaskovic Z.; Dewhirst M. W.; Li C. Y. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell, 2007, 26(1), 63-74.
48. Illi B.; Colussi C.; Grasselli A.; Farsetti A.; Capogrossi M. C.; Gaetano C. NO sparks off chromatin: Tales of a multifaceted epigenetic regulator. Pharmacol. Ther., 2009, 123(3), 344-352.
49. Arif M.; Vedamurthy B. M.; Choudhari R.; Ostwal Y. B.; Mantelingu K.; Kodaganur G. S.; Kundu T. K. Nitric oxide-mediated histone hyperacetylation in oral cancer: Target for a water-soluble HAT inhibitor, CTK7A. Chem. Biol., 2010, 17(8), 903-913.
50. Vecellio M.; Meraviglia V.; Nanni S.; Barbuti A.; Scavone A.; DiFrancesco D.; Farsetti A.; Pompilio G.; Colombo G. I.; Capogrossi M. C.; Gaetano C.; Rossini A. In vitro epigenetic reprogramming of human cardiac mesenchymal stromal cells into functionally competent cardiovascular precursors. PLoS One, 2012, 7(12), e51694.
51. Vasudevan D.; Hickok J. R.; Bovee R. C.; Pham V.; Mantell L. L.; Bahroos N.; Kanabar P.; Cao X. J.; Maienschein-Cline M.; Garcia B. A.; Thomas D. D. Nitric oxide regulates gene expression in cancers by controlling histone posttranslational modifications. Cancer Res., 2015, 75(24), 5299-5308.
52. Kisley L. R.; Barrett B. S.; Bauer A. K.; Dwyer-Nield L. D.; Barthel B.; Meyer A. M.; Thompson D. C.; Malkinson A. M. Genetic ablation of inducible nitric oxide synthasedecreases mouse lung tumorigenesis. Cancer Res., 2002, 62(23), 6850-6856.
53. Ahn B.; Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res., 2001, 61(23), 8357-8360.
54. Zhang X. M.; Xu Q. Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res., 2001, 11(6), 559-567.
55. Ambs S.; Merriam W. G.; Ogunfusika M. O.; Bennett W. P.; Ishibe N.; Hussain S. P.; Tzeng E. E.; Geller D. A.; Billiar T. R.; Harris C. C. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med., 1998, 4(12), 1371-1376.
56. Hofseth L. J.; Hussain S. P.; Wogan G. N.; Harris C. C. Nitric oxide in cancer and chemoprevention. Free Radic. Biol. Med., 2003, 34(8), 955-968.
57. Crowell J. A.; Steele V. E.; Sigman C. C.; Fay J. R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther., 2003, 2(8), 815-823.
58. Scott D. J.; Hull M. A.; Cartwright E. J.; Lam W. K.; Tisbury A.; Poulsom R.; Markham A. F.; Bonifer C.; Coletta P. L. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology, 2001, 121(4), 889-899.
59. Hussain S. P.; Trivers G. E.; Hofseth L. J.; He P.; Shaikh I.; Mechanic L. E.; Doja S.; Jiang W.; Subleski J.; Shorts L.; Haines D.; Laubach V. E.; Wiltrout R. H.; Djurickovic D.; Harris C. C. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res., 2004, 64(19), 6849-6853.
60. Lagares-Garcia J. A.; Moore R. A.; Collier B.; Heggere M.; Diaz F.; Qian F. Nitric oxide synthase as a marker in colorectal carcinoma. Am. Surg., 2001, 67(7), 709-713.
61. Mazzoni A.; Bronte V.; Visintin A.; Spitzer J. H.; Apolloni E.; Serafini P.; Zanovello P.; Segal D. M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol., 2002, 168(2), 689-695.
62. Wigginton J. M.; Kuhns D. B.; Back T. C.; Brunda M. J.; Wiltrout R. H.; Cox G. W. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res., 1996, 56(5), 1131-1136.
63. Jayaraman P.; Alfarano M. G.; Svider P. F.; Parikh F.; Lu G.; Kidwai S.; Xiong H.; Sikora A. G. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFbeta1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity. Clin. Cancer Res., 2014, 20(24), 6439-6451.
64. Ambs S.; Merriam W. G.; Bennett W. P.; Felley-Bosco E.; Ogunfusika M. O.; Oser S. M.; Klein S.; Shields P. G.; Billiar T. R.; Harris C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res., 1998, 58(2), 334-341.
65. Raspollini M. R.; Amunni G.; Villanucci A.; Boddi V.; Baroni G.; Taddei A.; Taddei G. L. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol. Oncol., 2004, 92(3), 806-812.
66. Brennan P. A.; Dennis S.; Poller D.; Quintero M.; Puxeddu R.; Thomas G. J. Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck, 2008, 30(2), 208-214.
67. Ekmekcioglu S.; Ellerhorst J. A.; Prieto V. G.; Johnson M. M.; Broemeling L. D.; Grimm E. A. Tumor iNOS predicts poor survival for stage III melanoma patients. Int. J. Cancer, 2006, 119(4), 861-866.
68. Connelly S. T.; Macabeo-Ong M.; Dekker N.; Jordan R. C.; Schmidt B. L. Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma. Oral Oncol., 2005, 41(3), 261-267.
69. Eyler C. E.; Wu Q.; Yan K.; MacSwords J. M.; Chandler-Militello D.; Misuraca K. L.; Lathia J. D.; Forrester M. T.; Lee J.; Stamler J. S.; Goldman S. A.; Bredel M.; McLendon R. E.; Sloan A. E.; Hjelmeland A. B.; Rich J. N. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell, 2011, 146(1), 53-66.
70. Puglisi M. A.; Cenciarelli C.; Tesori V.; Cappellari M.; Martini M.; Di Francesco A. M.; Giorda E.; Carsetti R.; Ricci-Vitiani L.; Gasbarrini A. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. J. Pathol., 2015, 236(4), 479-490.
71. Di Francesco A. M.; Toesca A.; Cenciarelli C.; Giordano A.; Gasbarrini A.; Puglisi M. A. Metabolic modification in gastrointestinal cancer stem cells: characteristics and therapeutic approaches. J. Cell Physiol., 2016, 231(10), 2081-2087.
72. Raber P. L.; Thevenot P.; Sierra R.; Wyczechowska D.; Halle D.; Ramirez M. E.; Ochoa A. C.; Fletcher M.; Velasco C.; Wilk A.; Reiss K.; Rodriguez P. C. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int. J. Cancer, 2014, 134(12), 2853-2864.
73. Greten T. F.; Manns M. P.; Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol., 2011, 11(7), 802-807.
74. Srivastava M. K.; Sinha P.; Clements V. K.; Rodriguez P.; Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res., 2010, 70(1), 68-77.
75. Rodriguez P. C.; Quiceno D. G.; Zabaleta J.; Ortiz B.; Zea A. H.; Piazuelo M. B.; Delgado A.; Correa P.; Brayer J.; Sotomayor E. M.; Antonia S.; Ochoa J. B.; Ochoa A. C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res., 2004, 64(16), 5839-5849.
76. Youn J. I.; Nagaraj S.; Collazo M.; Gabrilovich D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol., 2008, 181(8), 5791-5802.
77. Gabrilovich D. I.; Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 2009, 9(3), 162-174.
78. Gabrilovich D. I.; Ostrand-Rosenberg S.; Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol., 2012, 12(4), 253-268.
79. Jayaraman P.; Parikh F.; Lopez-Rivera E.; Hailemichael Y.; Clark A.; Ma G.; Cannan D.; Ramacher M.; Kato M.; Overwijk W. W.; Chen S. H.; Umansky V. Y.; Sikora A. G. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J. Immunol., 2012, 188(11), 5365-5376.
80. Hirano K.; Hosoi A.; Matsushita H.; Iino T.; Ueha S.; Matsushima K.; Seto Y.; Kakimi K. The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic Tlymphocyte immunotherapy. Oncoimmunology, 2015, 4(8), e1019195.
81. Ito H.; Ando T.; Seishima M. Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosyl-ceramide in established murine cancer model. Oncotarget, 2015, 6(39), 41863-41874.
82. Ito H.; Ando T.; Ogiso H.; Arioka Y.; Seishima M. Inhibition of induced nitric oxide synthase enhances the antitumor effects on cancer immunotherapy using TLR7 agonist in mice. Cancer Immunol. Immunother., 2015, 64(4), 429-436.
83. Molon B.; Viola A.; Bronte V. Smoothing T cell roads to the tumor: Chemokine post-translational regulation. Oncoimmunology, 2012, 1(3), 390-392.
84. Molon B.; Ugel S.; Del P. F.; Soldani C.; Zilio S.; Avella D.; De P. A.; Mauri P.; Monegal A.; Rescigno M.; Savino B.; Colombo P.; Jonjic N.; Pecanic S.; Lazzarato L.; Fruttero R.; Gasco A.; Bronte V.; Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med., 2011, 208(10), 1949-1962.
85. Gehad A. E.; Lichtman M. K.; Schmults C. D.; Teague J. E.; Calarese A. W.; Jiang Y.; Watanabe R.; Clark R. A. Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J. Invest. Dermatol., 2012, 132(11), 2642-2651.
86. Afanasiev O. K.; Nagase K.; Simonson W.; Vandeven N.; Blom A.; Koelle D. M.; Clark R.; Nghiem P. Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J. Invest. Dermatol., 2013, 133(8), 2065-2073.
87. Nagaraj S.; Gupta K.; Pisarev V.; Kinarsky L.; Sherman S.; Kang L.; Herber D. L.; Schneck J.; Gabrilovich D. I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med., 2007, 13(7), 828-835.
88. Madhurantakam C.; Duru A. D.; Sandalova T.; Webb J. R.; Achour A. Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex. PLoS One, 2012, 7(3), e32805.
89. Hardy L. L.; Wick D. A.; Webb J. R. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR-or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J. Immunol., 2008, 180(9), 5956-5962.
90. Kasic T.; Colombo P.; Soldani C.; Wang C. M.; Miranda E.; Roncalli M.; Bronte V.; Viola A. Modulation of human T-cell functions by reactive nitrogen species. Eur. J. Immunol. 2011, 41(7), 1843-1849.
91. Macphail S. E.; Gibney C. A.; Brooks B. M.; Booth C. G.; Flanagan B. F.; Coleman J. W. Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression. J. Immunol., 2003, 171(9), 4809-4815.
92. Bingisser R. M.; Tilbrook P. A.; Holt P. G.; Kees U. R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol., 1998, 160(12), 5729-5734.
93. Niedbala W.; Cai B.; Liew F. Y. Role of nitric oxide in the regulation of T cell functions. Ann. Rheum. Dis., 2006, 65 (Suppl 3), iii37-iii40.
94. Niedbala W.; Cai B.; Liu H.; Pitman N.; Chang L.; Liew F. Y. Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. Proc. Natl. Acad. Sci. USA, 2007, 104(39), 15478-15483.
95. Mills C. D.; Kincaid K.; Alt J. M.; Heilman M. J.; Hill A. M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol., 2000, 164(12), 6166-6173.
96. Sica A.; Rubino L.; Mancino A.; Larghi P.; Porta C.; Rimoldi M.; Solinas G.; Locati M.; Allavena P.; Mantovani A. Targeting tumour-associated macrophages. Exp. Opin. Ther. Targets, 2007, 11(9), 1219-1229.
97. Biswas S. K.; Sica A.; Lewis C. E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol,. 2008, 180(4), 2011-2017.
98. Murray P. J.; Wynn T. A. Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol., 2011, 89(4), 557-563.
99. Qualls J. E.; Murray P. J. Tumor macrophages protective and pathogenic roles in cancer development. Curr. Top. Dev. Biol., 2011, 94, 309-328.
100. Keller R.; Geiges M.; Keist R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res., 1990, 50(5), 1421-1425.
101. Higuchi M.; Higashi N.; Taki H.; Osawa T. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J. Immunol., 1990, 144(4), 1425-1431.
102. Cui S.; Reichner J. S.; Mateo R. B.; Albina J. E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or-independent mechanisms. Cancer Res., 1994, 54(9), 2462-2467.
103. Lum H. D.; Buhtoiarov I. N.; Schmidt B. E.; Berke G.; Paulnock D. M.; Sondel P. M.; Rakhmilevich A. L. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factoralpha. Immunology, 2006, 118(2), 261-270.
104. Weiss J. M.; Ridnour L. A.; Back T.; Hussain S. P.; He P.; Maciag A. E.; Keefer L. K.; Murphy W. J.; Harris C. C.; Wink D. A.; Wiltrout R. H. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med., 2010, 207(11), 2455-2467.
105. Klug F.; Prakash H.; Huber P. E.; Seibel T.; Bender N.; Halama N.; Pfirschke C.; Voss R. H.; Timke C.; Umansky L.; Klapproth K.; Schakel K.; Garbi N.; Jager D.; Weitz J.; Schmitz-Winnenthal H.; Hammerling G. J.; Beckhove P. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell, 2013, 24(5), 589-602.
106. Prakash H.; Klug F.; Nadella V.; Mazumdar V.; Schmitz-Winnenthal H.; Umansky L. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. Carcinogenesis, 2016, 37(3), 301-313.
107. Thomas W. J.; Thomas D. L.; Knezetic J. A.; Adrian T. E. The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells. Pancreas, 2002, 24(2), 161-168.
108. Bulotta S.; Barsacchi R.; Rotiroti D.; Borgese N.; Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J. Biol. Chem., 2001, 276(9), 6529-6536.
109. de Wilt J. H.; Manusama E. R.; van E. B.; van Tiel S. T.; Jorna A. S.; Seynhaeve A. L.; ten Hagen T. L.; Eggermont A. M. Nitric oxide synthase inhibition results in synergistic antitumour activity with melphalan and tumour necrosisfactor alpha-based isolated limb perfusions. Br. J. Cancer, 2000, 83(9), 1176-1182.
110. Bonavida B.; Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemoimmunotherapeutics. Redox. Biol., 2015, 6, 486-494.
111. Garban H. J.; Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: A pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J. Immunol., 2001, 167(1), 75-81.
112. Garban H. J.; Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol. Oncol., 1999, 73(2), 257-264.
113. Huerta-Yepez S.; Vega M.; Escoto-Chavez S. E.; Murdock B.; Sakai T.; Baritaki S.; Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide, 2009, 20(1), 39-52.
114. Kashiwagi S.; Izumi Y.; Gohongi T.; Demou Z. N.; Xu L.; Huang P. L.; Buerk D. G.; Munn L. L.; Jain R. K.; Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest., 2005, 115(7), 1816-1827.
115. Padera T. P.; Stoll B. R.; Tooredman J. B.; Capen D.; di T. E.; Jain R. K. Pathology: cancer cells compress intratumour vessels. Nature, 2004, 427(6976), 695.
116. Franchi A.; Massi D.; Santucci M.; Masini E.; Rossi D. D.; Magnelli L.; Fanti E.; Naldini A.; Ardinghi C.; Carraro F.; Gallo O. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J. Pathol., 2006, 208(3), 439-445.
117. Nakamura Y.; Yasuoka H.; Tsujimoto M.; Yoshidome K.; Nakahara M.; Nakao K.; Nakamura M.; Kakudo K. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin. Cancer Res., 2006, 12(4), 1201-1207.
118. Nakamura Y.; Yasuoka H.; Zuo H.; Takamura Y.; Miyauchi A.; Nakamura M.; Kakudo K. Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis. J. Clin. Endocrinol. Metab., 2006, 91(4), 1582-1585.
119. Hobbs A. J.; Higgs A.; Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol., 1999, 39(191-220.
120. Beeharry N.; Chambers J. A.; Faragher R. G.; Garnett K. E.; Green I. C. Analysis of cytokine-induced NOdependent apoptosis using RNA interference or inhibition by 1400W. Nitric Oxide, 2004, 10(2), 112-118.
121. Wu J.; Akaike T.; Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res., 1998, 58(1), 159-165.
122. Zhang H. J.; Zhao W.; Venkataraman S.; Robbins M. E.; Buettner G. R.; Kregel K. C.; Oberley L. W. Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. J. Biol. Chem., 2002, 277(23), 20919-20926.
123. Gallo O.; Masini E.; Morbidelli L.; Franchi A.; Fini-Storchi I.; Vergari W. A.; Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst., 1998, 90(8), 587-596.
124. Jadeski L. C.; Hum K. O.; Chakraborty C.; Lala P. K. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int. J. Cancer, 2000, 86(1), 30-39.
125. Jadeski L. C.; Lala P. K. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol., 1999, 155(4), 1381-1390.
126. Swaroop G. R.; Kelly P. A.; Bell H. S.; Shinoda J.; Yamaguchi S.; Whittle I. R. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br. J. Neurosurg., 2000, 14(6), 543-548.
127. Rao C. V.; Kawamori T.; Hamid R.; Reddy B. S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis, 1999, 20(4), 641-644.
128. Rao C. V.; Indranie C.; Simi B.; Manning P. T.; Connor J. R.; Reddy B. S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 2002, 62(1), 165-170.
129. Rao C. V. Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res., 2004, 555(1-2), 107-119.
130. Inano H.; Onoda M. Nitric oxide produced by inducible nitric oxide synthase is associated with mammary tumorigenesis in irradiated rats. Nitric Oxide, 2005, 12(1), 15-20.
131. Chen T.; Nines R. G.; Peschke S. M.; Kresty L. A.; Stoner G. D. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Res., 2004, 64(10), 3714-3717.
132. Bronte V.; Kasic T.; Gri G.; Gallana K.; Borsellino G.; Marigo I.; Battistini L.; Iafrate M.; Prayer-Galetti T.; Pagano F.; Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med., 2005, 201(8), 1257-1268.
133. Serafini P.; Meckel K.; Kelso M.; Noonan K.; Califano J.; Koch W.; Dolcetti L.; Bronte V.; Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med., 2006, 203(12), 2691-2702.
134. Singh R.; Pervin S.; Karimi A.; Cederbaum S.; Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res., 2000, 60(12), 3305-3312.
135. Xie K.; Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic. Biol. Med., 2003, 34(8), 969-986.
136. Edwards P.; Cendan J. C.; Topping D. B.; Moldawer L. L.; MacKay S.; Copeland E. M. I. I.; Lind D. S. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J. Surg. Res., 1996, 63(1), 49-52.
137. Harmey J. H.; Bucana C. D.; Lu W.; Byrne A. M.; McDonnell S.; Lynch C.; Bouchier-Hayes D.; Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer, 2002, 101(5), 415-422.
138. Shannon A. M.; Bouchier-Hayes D. J.; Condron C. M.; Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev., 2003, 29(4), 297-307.
139. Brown J. M.; Wilson W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4(6), 437-447.
140. Sullivan R.; Pare G. C.; Frederiksen L. J.; Semenza G. L.; Graham C. H. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requireshypoxia-inducible factor-1 activity. Mol. Cancer Ther., 2008, 7(7), 1961-1973.
141. Talks K. L.; Turley H.; Gatter K. C.; Maxwell P. H.; Pugh C. W.; Ratcliffe P. J.; Harris A. L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 2000, 157(2), 411-421.
142. Sogawa K.; Numayama-Tsuruta K.; Ema M.; Abe M.; Abe H.; Fujii-Kuriyama Y. Inhibition of hypoxiainducible factor 1 activity by nitric oxide donors in hypoxia. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7368-7373.
143. Agani F. H.; Puchowicz M.; Chavez J. C.; Pichiule P.; La-Manna J. Role of nitric oxide in the regulation of HIF-1alpha expression during hypoxia. Am. J. Physiol. Cell Physiol., 2002, 283(1), C178-C186.
144. Mitchell J. B.; Wink D. A.; DeGraff W.; Gamson J.; Keefer L. K.; Krishna M. C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res., 1993, 53(24), 5845-5848.
145. De R. M.; Verellen D.; Verovski V.; Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide, 2008, 19(2), 164-169.
146. De R. M.; Van E. G.; Engels B.; Verovski V.; Storme G. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway. Bull. Cancer, 2008, 95(3), 282-291.
147. Riganti C.; Miraglia E.; Viarisio D.; Costamagna C.; Pescarmona G.; Ghigo D.; Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res., 2005, 65(2), 516-525.
148. Gottesman M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53(615-627.
149. Moitra K.; Lou H.; Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther., 2011, 89(4), 491-502.
150. Riganti C.; Rolando B.; Kopecka J.; Campia I.; Chegaev K.; Lazzarato L.; Federico A.; Fruttero R.; Ghigo D. Mitochondrial-targeting nitrooxy-doxorubicin: A new approach to overcome drug resistance. Mol. Pharm., 2013, 10(1), 161-174.
151. Fruttero R.; Crosetti M.; Chegaev K.; Guglielmo S.; Gasco A.; Berardi F.; Niso M.; Perrone R.; Panaro M. A.; Colabufo N. A. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J. Med. Chem., 2010, 53(15), 5467-5475.
152. Jain R. K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 2005, 307(5706), 58-62.
153. Wang Z.; Cook T.; Alber S.; Liu K.; Kovesdi I.; Watkins S. K.; Vodovotz Y.; Billiar T. R.; Blumberg D. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res., 2004, 64(4), 1386-1395.
154. Jordan B. F.; Sonveaux P.; Feron O.; Gregoire V.; Beghein N.; Dessy C.; Gallez B. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int. J. Cancer, 2004, 109(5), 768-773.
155. Sonveaux P.; Dessy C.; Brouet A.; Jordan B. F.; Gregoire V.; Gallez B.; Balligand J. L.; Feron O. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J., 2002, 16(14), 1979-1981.
156. Lee D. H.; Pfeifer G. P. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis, 2007, 22(1), 63-67.
157. Sharma K.; Chakrapani H. Site-directed delivery of nitric oxide to cancers. Nitric Oxide, 2014, 43, 8-16.
158. Huerta S.; Chilka S.; Bonavida B. Nitric oxide donors: novel cancer therapeutics (review). Int. J. Oncol., 2008, 33(5), 909-927.
159. Hou Y.; Wang J.; Andreana P. R.; Cantauria G.; Tarasia S.; Sharp L.; Braunschweiger P. G.; Wang P. G. Targeting nitric oxide to cancer cells: cytotoxicity studies of glyco-Snitrosothiols. Bioorg. Med. Chem. Lett., 1999, 9(15), 2255-2258.
160. Lu D.; Nadas J.; Zhang G.; Johnson W.; Zweier J. L.; Cardounel A. J.; Villamena F. A.; Wang P. G. 4-Aryl-1, 3, 2-oxathiazolylium-5-olates as pH-controlled NO-donors: The next generation of S-nitrosothiols. J. Am. Chem. Soc., 2007, 129(17), 5503-5514.
161. McMurtry V.; Saavedra J. E.; Nieves-Alicea R.; Simeone A. M.; Keefer L. K.; Tari A. M. JS-K, a nitric oxidereleasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int. J. Oncol., 2011, 38(4), 963-971.
162. Nandurdikar R. S.; Maciag A. E.; Holland R. J.; Cao Z.; Shami P. J.; Anderson L. M.; Keefer L. K.; Saavedra J. E. Structural modifications modulate stability of glutathioneactivated arylated diazeniumdiolate prodrugs. Bioorg. Med. Chem., 2012, 20(9), 3094-3099.
163. Shami P. J.; Saavedra J. E.; Bonifant C. L.; Chu J.; Udupi V.; Malaviya S.; Carr B. I.; Kar S.; Wang M.; Jia L.; Ji X.; Keefer L. K. Antitumor activity of JS-K [O2-(2, 4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]dia-zen-1-ium-1, 2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J. Med. Chem., 2006, 49(14), 4356-4366.
164. Nandurdikar R. S.; Keefer L. K.; Saavedra J. E. Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO. Chem. Commun. (Camb.), 2011, 47(23), 6710-6712.
165. Cai T. B.; Lu D.; Landerholm M.; Wang P. G. Sialated diazeniumdiolate: A new sialidase-activated nitric oxide donor. Org. Lett., 2004, 6(23), 4203-4205.
166. Moharram S.; Zhou A.; Wiebe L. I.; Knaus E. E. Design and synthesis of 3'-and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents. J. Med. Chem., 2004, 47(7), 1840-1846.
167. Aguirre G.; Boiani M.; Cerecetto H.; Fernandez M.; Gonzalez M.; Leon E.; Pintos C.; Raymondo S.; Arredondo C.; Pacheco J. P.; Basombrio M. A. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies. Pharmazie, 2006, 61(1), 54-59.
168. Sumitani K.; Kamijo R.; Nagumo M. Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb protooncogene expression. Anticancer Res., 1997, 17(2A), 865-871.
169. Blackburn R. V.; Galoforo S. S.; Berns C. M.; Motwani N. M.; Corry P. M.; Lee Y. J. Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer, 1998, 82(6), 1137-1145.
170. Zhang C. X.; Lippard S. J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol., 2003, 7(4), 481-489.
171. Hirst D.; Robson T. Targeting nitric oxide for cancer therapy. J. Pharm. Pharmacol., 2007, 59(1), 3-13.
172. Hirst D. G.; Robson T. Nitrosative stress in cancer therapy. Front. Biosci., 2007, 12, (3406-3418.
173. Fiorucci S.; Del S. P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig. Liver Dis., 2003, 35(Suppl) 2, S9-19.
174. Fiorucci S.; Santucci L.; Gresele P.; Faccino R. M.; Del S. P.; Morelli A. Gastrointestinal safety of NOaspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterology, 2003, 124(3), 600-607.
175. Williams J. L.; Kashfi K.; Ouyang N.; Del S. P.; Kopelovich L.; Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun., 2004, 313(3), 784-788.
176. Hundley T. R.; Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther., 2006, 316(1), 25-34.
177. McIlhatton M. A.; Tyler J.; Burkholder S.; Ruschoff J.; Rigas B.; Kopelovich L.; Fishel R. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res., 2007, 67(22), 10966-10975.
178. Wallace J. L.; Vergnolle N.; Muscara M. N.; Asfaha S.; Chapman K.; McKnight W.; Del S. P.; Morelli A.; Fiorucci S. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology, 1999, 117(3), 557-566.
179. De S.C.; Serafini P.; Marigo I.; Dolcetti L.; Bolla M.; Del S. P.; Melani C.; Guiducci C.; Colombo M. P.; Iezzi M.; Musiani P.; Zanovello P.; Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA, 2005, 102(11), 4185-4190.
180. Rapozzi V.; Della P. E.; Bonavida B. Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy. Redox. Biol., 2015, 6(311-317.
181. Rapozzi V.; Della P. E.; Zorzet S.; Zacchigna M.; Bonavida B.; Xodo L. E. Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide, 2013, 30(26-35.
182. Carneiro Z. A.; de Moraes J. C.; Rodrigues F. P.; de Lima R. G.; Curti C.; da Rocha Z. N.; Paulo M.; Bendhack L. M.; Tedesco A. C.; Formiga A. L.; da Silva R. S. Photocytotoxic activity of a nitrosyl phthalocyanine ruthenium complex-a system capable of producing nitric oxide and singlet oxygen. J. Inorg. Biochem., 2011, 105(8), 1035-1043.
183. Giles N. M.; Kumari S.; Gang B. P.; Yuen C. W.; Billaud E. M.; Giles G. I. The molecular design of Snitrosothiols as photodynamic agents for controlled nitric oxide release. Chem. Biol. Drug Des., 2012, 80(3), 471-478.
184. Brown J. M. Tumor hypoxia in cancer therapy. Methods Enzymol., 2007, 435, 297-321.
185. Gate L.; Tew K. D. Glutathione S-transferases as emerging therapeutic targets. Expert. Opin. Ther. Target, 2001, 5(4), 477-489.
186. Townsend D. M.; Findlay V. L.; Tew K. D. Glutathione Stransferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol., 2005, 401(287-307.
187. Shami P. J.; Saavedra J. E.; Wang L. Y.; Bonifant C. L.; Diwan B. A.; Singh S. V.; Gu Y.; Fox S. D.; Buzard G. S.; Citro M. L.; Waterhouse D. J.; Davies K. M.; Ji X.; Keefer L. K. JS-K, a glutathione/glutathione S-transferaseactivated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol. Cancer Ther., 2003, 2(4), 409-417.
188. Kiziltepe T.; Hideshima T.; Ishitsuka K.; Ocio E. M.; Raje N.; Catley L.; Li C. Q.; Trudel L. J.; Yasui H.; Vallet S.; Kutok J. L.; Chauhan D.; Mitsiades C. S.; Saavedra J. E.; Wogan G. N.; Keefer L. K.; Shami P. J.; Anderson K. C. JSK, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood, 2007, 110(2), 709-718.
189. Kiziltepe T.; Anderson K. C.; Kutok J. L.; Jia L.; Boucher K. M.; Saavedra J. E.; Keefer L. K.; Shami P. J. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol., 2010, 62(1), 145-151.
190. Fionda C.; Abruzzese M. P.; Zingoni A.; Soriani A.; Ricci B.; Molfetta R.; Paolini R.; Santoni A.; Cippitelli M. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC. Cancer, 2015, 15(17.
191. Arrieta O.; Blake M.; de la Mata-Moya MD; Corona F.; Turcott J.; Orta D.; Alexander-Alatorre J.; Gallardo-Rincon D. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer. Radiother. Oncol., 2014, 111(2), 311-315.
192. Siemens D. R.; Heaton J. P.; Adams M. A.; Kawakami J.; Graham C. H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology, 2009, 74(4), 878-883.